Patents on NGTs, between disputes and desire: the case of Crispr-Cas 9
By Denis MESHAKA
Published on the 16/09/2024
Share
The patent rights applying to NGTs are vast and complex. They are also precious to a few multinational companies that want to control the economy of the sector. The illustration with Crispr-Cas.
This content is restricted to site members. If you are an existing user, please log in. New users may register below.
